Company news
Theralase Technologies Inc. (TSXV:TLT) news
Theralase Technologies Inc. news releases on 6ix. Latest, Sep 18, 2026: Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements
Press releases & updates
Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements
September 18, 2026
Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)
September 15, 2026
Theralase(R) Releases Q2 2026 Financial Statements
August 28, 2026
Theralase(R) Closes C$3.6 Million Brokered Financing
August 24, 2026
Theralase(R) Announces $5 Million Brokered LIFE Offering
August 10, 2026
Theralase(R) Engages Global One Media to Expand Global Investor Awareness
August 4, 2026
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
June 30, 2026
Theralase(R) Lists Warrants on the TSXV
June 3, 2026
Theralase(R) Releases Q1 2026 Financial Statements
May 29, 2026
Theralase Technologies : ® Releases Q1 2026 Financial Statements
May 28, 2026
Theralase(R) Closes C$4.8 Million Offering
May 20, 2026
Theralase Technologies : ® Closes C$4.8 Million Offering
May 19, 2026
Theralase(R) Announces $4 Million Brokered LIFE Offering
May 5, 2026
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
May 4, 2026
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
April 13, 2026
Theralase(R) Closes $CAN 2.66 Million Financing
April 10, 2026
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
March 17, 2026
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
March 10, 2026
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
March 9, 2026
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
March 2, 2026
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
February 20, 2026
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
February 17, 2026
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
February 10, 2026
Theralase(R) Provides Update on Bladder Cancer Clinical Study
February 4, 2026
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
February 2, 2026
Canadian Investment Regulatory Organization Trade Resumption - TLT
January 12, 2026
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
January 12, 2026
Canadian Investment Regulatory Organization Trading Halt - TLT
January 9, 2026
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
December 23, 2025
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
December 12, 2025
Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
November 24, 2025
Theralase(R) Investor Conference Call Reminder
November 17, 2025
Theralase(R) Releases 3Q2025 Financial Statements
November 10, 2025
Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug
November 3, 2025
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
September 24, 2025
Theralase(R) Extends Warrants
August 29, 2025
Theralase(R) Releases 2Q2025 Financial Statements
August 26, 2025
Theralase(R) Closes Non-Brokered Private Placement
July 28, 2025
Theralase Completes Annual General and Special Meeting
June 12, 2025
Theralase Annual General Meeting
June 5, 2025
Theralase(R) 1Q2025 Financial Statements
May 30, 2025
CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
May 29, 2025
Theralase to Present Groundbreaking Research at ASTRO 2025
May 28, 2025
Theralase Provides Corporate Update
May 20, 2025
Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
May 5, 2025
Theralase Discovers New Mechanism of Action of Lead Drug
April 28, 2025
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
April 10, 2025
Ruvidar Demonstrates 7 Year Complete Response
April 7, 2025
Ruvidar Effective in the Treatment of Herpes
March 24, 2025
Theralase(R) Releases 2024 Annual Financial Statements
March 12, 2025